Since the beginning of the pandemic in Bangladesh, Prof Dr Mohammed Tarek Alam, Head of Medicine at Bangladesh Medical College, started to explore the treatment of coronavirus with a team of 19 doctors and researchers. Along with Dr Rubaiul Murshed, Professor of Healthcare Management and Chairperson of Shomman Foundation, he has been researching the use of Ivermectin for Covid-19 patients as the co-primary investigator on a study being conducted by IEDCR and as a member of the advisory board of a study by ICDDR,B. In an interview with The Daily Star, the two medical professionals spoke about what they are calling “the people’s medicine” for treating Covid-19 and the general situation of coronavirus in Bangladesh.
Why Ivermectin?
We first learnt about the multifaceted properties of Ivermectin, along with its unique capability of decreasing the virulence of Covid-19, in a paper published in early April by Monash University, Australia (Caly et al). Ivermectin had already been used before in Thailand, Australia and some other countries to treat SARS, Zika and dengue. On April 15, Dr Alam informed a colleague (who was Covid positive) about the newly established findings of the FDA approved drug, who then agreed to take the medicine in combination with Doxycycline (as directed).
The use of this medication yielded positive results, after which it was expanded to other Covid-19 positive doctors and interns with their consent. Within five to seven days we saw the benefits in over 50 patients, and the results were published in a research paper in the Bangladesh College of Physicians and Surgeons (BCPS) journal in July 2020. This treatment was also replicated at the Police Hospital and saw over a 90 percent success rate.
Why do you call it the “people’s medicine”?
We call it that because the combination therapy of Ivermectin and Doxycycline costs around Tk 50-75. Shomman Foundation has already started distributing the drugs free of cost to the underprivileged. During the monsoon floods in Sylhet, under the supervision of the Sylhet regional health director, the drug combination was administered to many affected people there.
This combination is also very safe—Ivermectin has minimum side effects, although its safety in pregnant and lactating women has not been established yet, and it is contraindicated in patients with chronic liver disease. Doxycycline is an antibiotic, but it possesses anti-inflammatory properties that can combat the coronavirus—its effect as an immune modulator is the main use here, and it is also not the sort of antibiotic that has been observed to create any cross-resistance.
Can this medicine act as a preventive?
We cannot say this with any certainty, but there is a possibility. It has been used as a preventive in onchocerciasis (river blindness) in sub-Saharan Africa. Its half life is about 16 hours in the blood, but studies in bovine lungs show that the medicine stays in the lungs for about 7-10 days, and even a residual amount could prevent certain infections, so there is a chance of it working as a prophylactic (preventive medicine).
Over 6,000 people have died from Covid-19 in Bangladesh and our infection and death rates have been constant for a while. Are you saying Ivermectin can change that?
There are different stages of coronavirus infection. It should be clarified that we are specifically focusing on the use of Ivermectin in the early stages of infection when the symptoms are starting to manifest, or when people are asymptomatic. When the infection has progressed and is in the second, more severe stage, hospitalisation is needed. At that point, only Ivermectin will obviously not work, and other interventions are needed—steroids to stop the cytokine storm, high flow oxygen, ICU care and even ventilators. All of this is extremely expensive and many hospitals charge exorbitant prices that are not in most people’s reach.
Coming to the hospital late could definitely be a factor in the continuing number of deaths from coronavirus in our country. For example, I (Dr Alam) had a patient (69 years) whose whole family got infected—the children were asymptomatic and the younger members recovered eventually, but when he came to me after 11 days of being infected, an X-ray showed that by that point, both his lungs had become greatly infected. So for people in the high-risk group, treatment must begin immediately.
However, we must remember that this is a really new disease and we are still learning the ways in which it affects us. There is a third stage of more long-term impacts (or what we call long Covid syndrome) that could manifest three to six months after hospitalisation—we have seen coronavirus have residual effects on the lungs, liver, kidney, heart, brain, peripheral nerves and mental health. So it would be simplistic to say that you just give the medicine and everything becomes okay.
It is true that although Covid-19 has had a huge impact on Bangladesh, perhaps it has not been as bad as we originally anticipated. What do you suppose the reason is behind this?
When the pandemic first began, we had a proper lockdown, and that definitely contributed to stemming the spread immediately. However, certain factors, such as the mass return of expatriates and movements between different areas of the country, meant we could not finally control it. However, we were also less prepared in the beginning—there was hardly any PPE or even masks, and you will remember that many Bangladeshi doctors lost their lives on the frontlines. We have more of these safety precautions in place now, and we have also learnt how to manage Covid-19 better.
There are also certain other hypotheses—its possible that already having the flu vaccine could make you less susceptible, lots of exposure to sunlight (vitamin D) could make you more immune. Some have suggested that people who live in places like slums or are constantly outdoors may have weaker immunity due to poor nutrition, but could also be more exposed to germs and as a result, have antibodies that make them more resistant to certain viruses.
It might sound like we are beating our own drums, but we believe the widespread use of Ivermectin has contributed as well, since a lot of places are already using this combination. However, we have observed that many pharmacies are just handing out Ivermectin without specifying the correct dosage and administration, and we must clarify that we do not support this.
Will there be a second wave? How hopeful are you about a vaccine coming out soon?
We don’t think there is any confusion about that—we are already seeing countries around the world deal with a second wave of the virus and we too, must be prepared. There is absolutely no alternative to physical distancing, regular hand washing and the wearing of masks. Too many people have become relaxed about these safety rules and there will definitely be consequences. We have to remember that getting a vaccine out is a long and complicated process and we are unlikely to have access before the next one or two years.
What should we do in the meantime? We have also seen our economy suffer in the first lockdown but if things get worse, we could require a second one. This is why we are really keen to do further research on the preventative potential of Ivermectin. We are not the only ones—even John Hopkins began a clinical trial in June. Can this medication keep the country going and the economy open? We should have a registry or a website where we can track who is using this combination, on how many patients, and what sort of impacts they are seeing, so we can collect and collate the data for research.
While we wait for the vaccine, we cannot become complacent. We urge everyone to maintain distance, wear masks, wash hands, be careful of air conditioned rooms without proper ventilation, avoid using crammed, closed spaces like elevators, and expose your body to the sun during midday for 30 minutes everyday or take an adequate dose of Vitamin D to boost the immune system (please seek medical advice prior to consumption to avoid toxic effects). We have to get used to this “new normal” and maintain safety standards at all times.
